Global Blood's sickle cell disease drug heads to FDA, as questions linger

Global Blood's sickle cell disease drug heads to FDA, as questions linger

STAT Plus: Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

By ADAM FEUERSTEIN

JONATHAN ARMSTRONG/WELLCOME

New clinical trial results will allow the company to file for accelerated approval, but not everyone is convinced patients will benefit.

READ MORE